EUVIMEDEUVIMED entdecken
Crossref

Temsirolimus is a promising immunomodulatory agent for enhanced transplantation outcomes

Xianguo Li, Zuojie Peng, Ke An, Mengjiao Xue, Zhenzhen Wang, Junjie Xia, Zhongquan Qi, Xiaogang Shu

Transplant Immunology · 2023

DOI: 10.1016/j.trim.2023.101952 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Immunology, 2023. Verfasst von Xianguo Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Hauptthemen laut MEDLINE: Interleukin-4, Sirolimus. Die Arbeit nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of the Jiangsu Higher Education Institutions of China, Outstanding Talent Research Funding of Xuzhou Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Identifying effective immunosuppressive strategies is critical for addressing immunological rejection following organ transplantation. This study explores the potential immunosuppressive effects and mechanisms of temsirolimus, a rapamycin derivative, in organ transplantation. METHODS: A mouse cardiac allograft model was established using a cervical cannula technique with BALB/c donors and C57BL/6 recipients. Mice were administered temsirolimus intragastrically and graft survival was evaluated. Histological staining was used to assess pathological changes. The BrdU assay was used to measure splenic T cell proliferation. Flow cytometry was used to quantify regulatory T cells (Tregs), CD4+ T cells, and CD8+ T cells. ELISA and qPCR assays were used to determine Foxp3, IL-4, IFN-γ, and TGF-β expression. RESULTS: Temsirolimus displayed potent immunosuppressive effects at 20 mg/kg/day, significantly inhibiting T cell proliferation (84.6%, P < 0.0001) and prolonging graft survival (median 49 days vs. 8.5 days in controls, P < 0.0001). However, median survival decreased to 34.5 days upon withdrawal. Temsirolimus also reduced splenic CD4+ and CD8+ T cells (2.85% and 2.92%, P < 0.001) and antibody levels (IgM, IgG1, IgG2) by 11.85-29.09% (P < 0.0001) and increased Tregs, Foxp3, IL-4 (P < 0.01), and TGF-β (P < 0.05), while decreasing IFN-γ (P < 0.001). CONCLUSIONS: Temsirolimus exhibited potent immunosuppressive effects, emerging as a strong candidate to mitigate organ transplant rejection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-4SirolimusMiceAnimalsMice, Inbred C57BLT-Lymphocytes, RegulatoryGraft SurvivalTransforming Growth Factor betaForkhead Transcription FactorsGraft RejectionMice, Inbred BALB C

Stichwörter der Autor:innen

Allograft survivalImmunosuppressive effectOrgan transplantationTemsirolimusTregs

Substanzen

temsirolimusInterleukin-4SirolimusTransforming Growth Factor betaForkhead Transcription Factors

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • Department of Physiology, Xuzhou Medical University, Xuzhou 221009, China.
  • Division of Ophthalmology and Vision Science, Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
  • Department of Pharmacy, Zhoukou Central Hospital, Zhoukou 466000, China.
  • Organ Transplantation Institute, Fujian Provincial Key Laboratory of Organ and Tissue Regeneration, School of Medicine, Xiamen University, Xiamen 361100, China. Electronic address: yxyyz@gxu.edu.cn.
  • Medical College of Guangxi University, Guangxi University, Nanning 530004, China. Electronic address: xia@xmu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of the Jiangsu Higher Education Institutions of China
  • Outstanding Talent Research Funding of Xuzhou Medical University
  • Natural Science Research of Jiangsu Higher Education Institutions of China
  • Xuzhou Medical University
  • Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions

Zitieren

APA

Li, X., Peng, Z., An, K., Xue, M., Wang, Z., Xia, J., Qi, Z., & Shu, X. (2023). Temsirolimus is a promising immunomodulatory agent for enhanced transplantation outcomes. Transplant Immunology. https://doi.org/10.1016/j.trim.2023.101952

Vancouver

Li X, Peng Z, An K, Xue M, Wang Z, Xia J, et al. Temsirolimus is a promising immunomodulatory agent for enhanced transplantation outcomes. Transplant Immunology. 2023. doi:10.1016/j.trim.2023.101952

BibTeX
@article{Li2023,
  author = {Li, Xianguo and Peng, Zuojie and An, Ke and Xue, Mengjiao and Wang, Zhenzhen and Xia, Junjie and Qi, Zhongquan and Shu, Xiaogang},
  title = {Temsirolimus is a promising immunomodulatory agent for enhanced transplantation outcomes},
  journal = {Transplant Immunology},
  year = {2023},
  doi = {10.1016/j.trim.2023.101952}
}
Kostenlos starten →